Quarterly Results

2021

  • Earnings Release

    • AnPac Bio 2021 First Half Revenue Up 128.5% with Non-GAAP Loss Reduced by 18.3%

    • Earnings Release

    AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed

    2020

    • Earnings Release

    AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss)

    • Earnings Release

    AnPac Bio Reports First Six Months of 2020 Financial Results

    Sign up for the Anpac Bio newsletter and receive our latest news.

    Quick Links

    Contact Information

    Anpac Technology USA (Anpac Bio)
    3 Spring House Innovation Park, Suite 150
    Ambler, PA 19002

    Email: [email protected]

    Phone Number: +1 (267) 810-6776

    Anpac Bio-Medical Science Co., Ltd.

    Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.

    ©2021 Anpac Bio-Medical Science Co., Ltd.